

earnings conference call second-quarter fiscal 2022



April 27, 2022 9:00 am ET

ashland.com / efficacy usability allure integrity profitability



Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "should," "plans" and "intends" and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, guarterly reports and other filings with the SEC, news releases and other written and oral communications. These forwardlooking statements are based on Ashland's expectations and assumptions, as of the date such statements are made, regarding Ashland's future operating performance, financial condition, and expected effects of the COVID-19 pandemic on Ashland's business, as well as the economy and other future events or circumstances. These statements include, but may not be limited to, the statements under Priorities and Outlook on pages 22 – 25 of the presentation, and Ashland's expectations regarding its ability to drive sales and earnings growth and realize further cost reductions. Ashland's expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the impact of acquisitions and/or divestitures, including the sale of the Performance Adhesives business, Ashland has made or may make (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland's substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland's future cash flows, results of operations, financial condition and its ability to repay debt); severe weather, natural disasters, public-health crises (including the current COVID-19 pandemic), cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters); the effects of the COVID-19 pandemic, and the ongoing Ukraine/Russia conflict, on the geographies in which we operate, the end markets we serve and on our supply chain and customers, and without limitation, risks and uncertainties affecting Ashland that are described in Ashland's most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland's website at http://investor.ashland.com or on the SEC's website at http://www.sec.gov. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. The extent and duration of the COVID-19 pandemic on our business and operations is uncertain. Factors that will influence the impact on our business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this presentation whether as a result of new information, future events or otherwise.

Regulation G: Adjusted Results

The information presented herein regarding certain unaudited adjusted results does not conform to generally accepted accounting principles in the United States (U.S. GAAP) and should not be construed as an alternative to the reported results determined in accordance with U.S. GAAP. Ashland has included this non-GAAP information to assist in understanding the operating performance of the company and its reportable segments. The non-GAAP information provided may not be consistent with the methodologies used by other companies. All non-GAAP information has been reconciled with reported U.S. GAAP results beginning on page 33 of this presentation.



agenda

- Q2 performance summary
- o Q2 financial results
- advancing our strategy
- o outlook
- closing comments
- o Q&A





Q2 performance summary



strong, resilient performance

in a world of accelerating change

resilient sales, profit and margins

exceeding pre-pandemic levels

strong cost recovery

in a high inflation environment


innovation

record number of new product introductions growing significantly





outstanding performance¹




Comparisons versus prior year. All figures are presented on an adjusted basis except Sales. Appendix B reconciles adjusted amounts to amounts reported under GAAP, including reconciliations of net income to EBITDA and adjusted EBITDA, operating income to adjusted operating income, income from continuing operations to adjusted income from continuing operations, diluted earnings per share to adjusted diluted earnings per share and adjusted diluted earnings per share, excluding amortization expense.



2 Unless otherwise noted, earnings are reported on a diluted-share basis.

6

growth across all business units




with adjusted EBITDA¹ significantly higher

1 Comparisons versus prior year.

2 Merchant sales represents 70% of Intermediates.

Q2-2022 Sales





Q2 financial results



fiscal-second quarter adjusted results¹

Ashland			
(\$US in millions, except percentages)	Q2 FY22	Q2 FY21	change
sales	\$604	\$509	+19 %
gross profit margin	36.4 %	31.4 %	+500 bps
SG&A / R&D costs / intangible amortization	\$119	\$103	+16 %
operating income	\$101	\$57	+77 %
EBITDA	\$163	\$116	+41 %
EBITDA margin	27.0 %	22.8 %	+420 bps
EPS (excluding acquisition amortization) ²	\$1.50	\$0.84	+79 %

• strong end-market demand, cost recovery in an inflationary environment, improved mix and Schülke & Mayr acquisition drove double-digit sales and earnings growth; FX a 3% headwind to sales

• increase in SARD expense due to the Schülke & Mayr acquisition, elimination of the INEOS transition services agreement and higher incentive accruals


o EBITDA up 41% to \$163 million compared to prior year

1 All figures are presented on an adjusted basis except Sales. Appendix B reconciles adjusted amounts to amounts reported under GAAP, including reconciliations of net income to EBITDA and adjusted EBITDA, operating income to adjusted operating income, income from continuing operations to adjusted income from continuing operations, diluted earnings per share to adjusted diluted earnings per share and adjusted diluted earnings per share, excluding amortization expense.



9

² Unless otherwise noted, earnings are reported on a diluted-share basis.



life sciences			
(\$US in millions, except percentages)	Q2 FY22	Q2 FY21	change
sales	\$204	\$185	+10 %
gross profit	\$73	\$64	+14 %
gross profit margin	35.8 %	34.6 %	+120 bps
operating Income	\$43	\$35	+23 %
EBITDA	\$58	\$50	+16 %
EBITDA margin	28.4 %	27.0 %	+140 bps

- improved cost recovery and enhanced mix plus strong pharma demand
- solid execution despite continued supply-chain and labor-availability challenges
- o gross margin and Adjusted EBITDA margin expansion
- Adjusted EBITDA growth to \$58 million



always solving


Q2 FY22 year-over-year Sales (HSD/MSD/LSD = high, mid or low single-digit %. DD = double-digit %)

10 ¹ All figures are presented on an adjusted basis except Sales. Appendix B reconciles adjusted amounts to amounts reported under GAAP, including reconciliations of net income to EBITDA and adjusted EBITDA, operating income to adjusted operating income.



personal care			
(\$US in millions, except percentages)	Q2 FY22	Q2 FY21	change
sales	\$172	\$137	+26 %
gross profit	\$67	\$49	+37 %
gross profit margin	39.0 %	35.8 %	+320 bps
operating Income	\$28	\$19	+47 %
EBITDA	\$49	\$38	+29 %
EBITDA margin	28.5 %	27.7 %	+80 bps


- strong customer demand, pricing and mix enhancements in core end markets; sales up 16% excluding acquisition and product exits (primarily in skin care)
- Schülke & Mayr acquisition continues to be a strong contributor to skin care growth
- earnings growth and margin expansion driven by cost recovery and mix improvements



always solving


Q2 FY22 year-over-year Sales (HSD/MSD/LSD = high, mid or low single-digit %. DD = double-digit %)

11 All figures are presented on an adjusted basis except Sales. Appendix B reconciles adjusted amounts to amounts reported under GAAP, including reconciliations of net income to EBITDA and adjusted EBITDA, operating income to adjusted operating income.



specialty additives			
(\$US in millions, except percentages)	Q2 FY22	Q2 FY21	change
sales	\$182	\$158	+15 %
gross profit	\$51	\$42	+21%
gross profit margin	28.0 %	26.6 %	+140 bps
operating Income	\$26	\$19	+37 %
EBITDA	\$48	\$40	+20 %
EBITDA margin	26.4 %	25.3 %	+110 bps


- strong demand, improved mix and cost recovery drove sales growth
- pricing and mix improvement across end markets led to margin expansion
- earnings growth despite inflation in raw materials, freight and energy costs and supplychain challenges



Q2 FY22 year-over-year Sales (HSD/MSD/LSD = high, mid or low single-digit %. DD = double-digit %)




12 All figures are presented on an adjusted basis except Sales. Appendix B reconciles adjusted amounts to amounts reported under GAAP, including reconciliations of net income to EBITDA and adjusted EBITDA, operating income to adjusted operating income.



13

intermediates			
(\$US in millions, except percentages)	Q2 FY22	Q2 FY21	change
sales	\$66	\$37	+78 %
gross profit	\$29	\$6	+383 %
gross profit margin	43.9 %	16.2 %	+2,770 bps
operating Income	\$27	\$3	+800 %
EBITDA	\$30	\$7	+329 %
EBITDA margin	45.5 %	18.9 %	+2,660 bps

- sales growth driven by significantly higher pricing across all product lines
- o captive sales of butanediol (BDO) transferred internally at current market-based prices
- higher earnings and expanded margins from higher pricing and improved mix, partially offset by overall cost inflation



always solvina

1 All figures are presented on an adjusted basis except Sales. Appendix B reconciles adjusted amounts to amounts reported under GAAP, including reconciliations of net income to EBITDA and adjusted EBITDA, operating income to adjusted operating income.

capital allocation discipline

Performance Adhesives sale closed on February 28

o gross proceeds of \$1.65 billion; net proceeds¹ of \$1.2 - \$1.3 billion

use of proceeds

- ~\$625 million of debt repayment since December 2021
- \$200 million open-market share repurchase
 - incremental to \$450 MM accelerated share repurchase completed on February 22
- \$35 million contributed to environmental trust

other long-term capital allocation priorities

- \$150 \$200 million growth capital investment over next 3 years
- increased flexibility to pursue future M&A strategy

Ashland has repurchased ~6.75 million shares (~11% outstanding) and reduced net leverage² from 3.6x to 1.3x since August 2021

- 1 Taxes payable of approximately \$320 million and transaction costs of approximately \$4 million to be paid in Q3 and Q4 of fiscal year 2022.
- 14 2 Net leverage defined as total debt less cash divided by trailing-twelve month Adjusted EBITDA. Current net leverage excludes taxes and transaction costs payable related to the sale of the Performance Adhesives business.





advancing our strategy



progress



disciplined pricing in an inflationary environment

improved mix management with widespread capacity constraints

improved planning despite challenging supply-chain issues





margin expansion and free cash flow conversion

refining innovation portfolio management process

advance M&A strategy and opportunity portfolio





innovation & growth

strong growth in new product introductions

alignment with markets and customer drivers

technology differentiation

strengthening innovation portfolio management





expanding cellulosic capacity

production capabilities beyond North America and Europe

robust 3-year growth capital plan underway





ESG progress

responsibly solving for a better world means Ashland is taking a leading global role in the supply of conscious specialty ingredients and ways of working



environment

- sourcing 90% key materials suppliers* are Ecovadis
- certified; naturally derived ingredients, sourced responsibly
- operations Nature Conservancy Plant a Billion Trees
- solutions 72% of Q2 new products are highly sustainable⁺



social

- established Responsible Solvers™ program
- announced innovative supplier partnership using STEM skills for sustainably farming guar
- Sponsored greenlight4girls- International Women's Day
- Nature Conservancy youth engagement lab sponsor

governance

- anti-boycott training for subject matter experts
- enterprise-wide global ethics ambassador program
- Ukraine- Russia sanctions and coordination with global incident management team (IMT)
- increased cyber security

* by spend

+ natural or nature-derived

defining Science Based Targets (SBTi)

BUSINESS 1.5°C

aligning operations with the ambitious aim of the Paris Climate Accord to limit global temperature rise to 1.5°C above preindustrial levels

- validating emissions data to ensure we set accurate targets for approval
- targets to be submitted for approval by end 2022





engaging in collaborative projects which advance the broader development goals of the United Nations, particularly the Sustainable Development Goals



ESG in action

STEM education and sustainable farming Sriganganagar district, Rajasthan, India



in-cosmetics global, Paris, France April 5 – 7, 2022




best functional ingredient BRONZE award

BRONZE







The Nature Conservancy forest restoration effort and





increased innovation speed & impact





- o record number of new product introductions
- o 100% of FY22 launches focused on growth
- 89% of the launches FY22 year-to-date are highly sustainable
- disciplined innovation process (project and portfolio management)
- business unit ownership of strategy and innovation priorities
- corporate oversight of portfolio and investments



recent new product introductions

award winning innovations



bio cellulose best functional ingredient

C Ashland



Ashland

BRONZE award

2022 Ringer award



styleze[™]es-1 polymer

2021 Henkel award for

sustainability



Ashland

Ashland



nature-derived

biodegradable

vegan

halal




natural

- organic biodegradable
- vegan
- COSMOS validated
- sustainably sourced

sensiva[™] go natural

- natural
- biodegradable
- vegan
- COSMOS validated



aquaflow™ eco

ESG as a business opportunity to unlocking sustainable, profitable growth



Ashland

nutrapress[™] chw

- organic chewable base
- sugar free
- allergen free
- vegan

biocide-free

packaging

CO2 reduction by

solid delivery form

recyclable paper



20

priorities

profitable growth

- rebalanced our innovation portfolio
- consumer-market focus
- intensifying ESG initiatives
- bolt-on M&A



margin expansion

- accelerate innovation growth
- value pricing
- mix improvement
- productivity



enhanced FCF

- prioritize organic growth CAPEX
- improved working capital efficiency
- strategically aligned M&A
- efficient balance sheet
- continued rewarding shareholders



intense commitment to environment, social and governance (ESG) as a growth driver





outlook



current macro trends

tailwinds

- o revenue
 - pricing a major driver
 - stable demand in life sciences, personal care, specialty additives and intermediates
 - capacity constraints support mix
 improvement
 - significant demand backlog allows for shifting supply of key products across segments
 - continuing to rebuild inventories
- plants operating well and producing more (sell or rebuild inventory)
- strong pricing action in place to cover existing and currently forecasted inflation
- raw-material availability challenging but improving
- some improvement in trucking availability and cost


headwinds

- impact of inflation control actions on economic growth and demand
- tight capacity limits volume growth
- continued supply-chain and logistics challenges
- lag impact of additional pricing actions to offset additional cost inflation
- o impact of Ukraine war
- China COVID lockdowns

difficult to forecast uncertain external risks (war escalation, lockdowns, energy & supply chain)



critical performance variables



demand remains strong, supply will drive revenue

energy inflation driving broad based pricing/cost inflation



outlook

full-year guidance maintained

forward looking insights

- o robust demand
 - strong order book
 - low inventory levels
- o pricing to address cost inflation
- no changes to underlying operating performance
- intermediates plant turnaround shifted from Q4 to Q3
- current model forecasts adj. EBITDA above range midpoint
- inflation, Russia / Ukraine war and China lockdowns - high level of uncertainty/difficult to forecast; room for upside/downside potential
- investing to support profitable growth

risks

- reliability / cost of ocean freight
- o rising global energy costs
- general cost inflation; foreign currency
- lag impact of pricing recover in Q4
- impact of Russia /Ukraine war and China lockdowns

agile, disciplined, focused on what we can control sales \$2.25 – \$2.35 billion adjusted EBITDA

\$550 – \$570 million





closing comments



Ashland

focused additives and specialty ingredients company

- o flexible, agile
- o consistent execution
- o solid growth
- o high margins
- o strong free cash flow

- leadership positions in high-quality markets and with exciting profitable growth opportunities
- str
 - strong technology, commercial and operations capabilities
 - global infrastructure
- s c
- compelling growth platforms with scale and sustainable competitive advantage
- stro
 - strong financial performance and cash flow generation
- \checkmark
 - experienced management team with proven track record and execution discipline
- \checkmark
- ESG is embedded in our strategy and operating plans



thank you and Q&A



appendix A: adjusted results summary and balance sheet



(\$US in millions, except percentages and per share data)	Q2 FY22	Q2 FY21	change
sales	\$604	\$509	+19 %
gross profit	\$220	\$160	+38 %
gross profit margin	36.4 %	31.4 %	+500 bps
SG&A / R&D costs / intangible amort.	\$119	\$103	+16 %
operating income	\$101	\$57	+77 %
depreciation & amortization	\$61	\$59	+3 %
EBITDA	\$163	\$116	+41 %
EBITDA margin	27.0 %	22.8 %	+420 bps
net interest and other expense	\$15	\$16	(6) %
effective tax rate	23 %	15 %	+800 bps
income from continuing operations	\$67	\$35	+91 %
income from continuing operations (excluding acquisition amortization)	\$86	\$52	+65 %
diluted share count (million shares)	57	62	(8) %
EPS (excluding acquisition amortization)	\$1.50	\$0.84	+79 %

All figures are presented on an adjusted basis except Sales and Diluted share count (million shares). Appendix B reconciles 1 adjusted amounts to amounts reported under GAAP, including reconciliations of net income to EBITDA and adjusted EBITDA, operating income to adjusted operating income, income from continuing operations to adjusted income from continuing operations, diluted earnings per share to adjusted diluted earnings per share and adjusted diluted earnings per share, excluding amortization expense.



30

Q2 business unit consolidation¹

(\$US in millions, except percentages)	Life Sciences	Personal Care	Specialty Additives	Inter- mediates	interco. eliminations	unallocated and other	Ashland	
sales	\$204	\$172	\$182	\$66	(\$20)	-	\$604	
gross profit	\$73	\$67	\$51	\$29	-	-	\$220	
gross profit margin	35.8 %	39.0 %	28.0 %	43.9 %	-	-	36.4 %	
EBITDA	\$58	\$49	\$48	\$30	-	(\$22)	\$163	
EBITDA margin	28.4 %	28.5 %	26.4 %	45.5 %	-	-	27.0 %	

- intercompany sales from intermediates to all other segments recorded at market pricing and are eliminated in consolidation
- unallocated and other includes legacy costs plus corporate governance (finance, legal, executive, etc.)
- o costs and assets aligned with primary business unit

¹ All figures are presented on an adjusted basis except Sales. Appendix B reconciles adjusted amounts to amounts reported under GAAP, including reconciliations of net income to EBITDA and adjusted EBITDA, operating income to adjusted operating income, income from continuing operations to adjusted income from continuing operations and diluted earnings per share to adjusted diluted earnings per share.



liquidity and net debt

(\$US in millions)	expiration	interest rate	Moody's rating	S&P rating	3/31/22 balance
cash					\$964
revolver and A/R facilities availability					692
cash, A/R and revolver availability ¹					\$1,656
US A/R sales program ¹					-
debt					
2.00% notes (EUR)	Jan. 2028	2.000%	Bal	BB+	\$558
3.375% notes	Sept. 2031	3.375%	Bal	BB+	450
6.875% notes	May 2043	6.875%	Bal	BB+	282
European A/R securitization	Aug. 2021	CP+70	-	-	-
revolving credit facility	Jan. 2025	L+137.5	-	-	-
6.50% junior subordinated notes	Jun. 2029	6.500%	B1	BB+	59
other ²		-	-	-	(13)
total debt			Ba1/stable	BB+/stable	\$1,336
cash					(964)
net debt					\$372

1 Total liquidity of \$1,656 million from all sources.

2 Includes \$16 million of debt issuance cost discounts as of March 31, 2022.



appendix B: non-GAAP reconciliation¹

1 Although Ashland provides forward looking guidance for adjusted EBITDA in this presentation, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort.



Ashland Global Holdings Inc. and Consolidated Subsidiaries **Reconciliation of Non-GAAP Data** for 12 Months Ended March 31, 2022

(\$ millions, except percentages)

Sales ¹	Q2 22	Q1 22	Q4 21	Q3 21	Total		Q2 21
Life Sciences \$	204	\$ 170	\$ 189	\$ 193	\$ 756		\$ 185
Personal Care	172	147	183	147	649		137
Specialty Additives	182	156	181	169	688		158
Intermediates	66	53	60	49	228		37
Less: Intercompany Eliminations	(20)	(14)	(22)	(15)	(71)		(8)
Total \$	604	\$ 512	\$ 591	\$ 543	\$ 2,250		\$ 509
						Adjusted EBITDA	
Adjusted EBITDA ¹	Q2 22	Q1 22	Q4 21	Q3 21	Total	Margin	Q2 21
Life Sciences \$	58	\$ 36	\$ 48	\$ 53	\$ 195	25.8%	\$ 50
Personal Care	49	36	51	39	175	27.0%	38
Specialty Additives	48	38	47	39	172	25.0%	40
Intermediates	30	19	21	15	85	37.3%	7
Unallocated	(22)	(23)	(18)	(17)	(80)		(19)
Total \$	163	\$ 106	\$ 149	\$ 129	\$ 547	24.3%	\$ 116

¹ Quarterly totals may not add to annual amounts due to rounding. Calculation of adjusted EBITDA for each period presented have been reconciled within certain financial filings with the SEC and posted on Ashland's website for each reportable segment.



34

Ashland Global Holdings Inc. and Consolidated Subsidiaries Segment Components of Key Items for Applicable Income Statement Captions for 3 Months Ended March 31, 2022

		Three Months Ended March 31, 2022										
(\$ millions)	Life So	Life Sciences		Personal Care		Specialty Additives	Intermediates		Unallocated & Other		Total	
OPERATING INCOME (LOSS)												
Operating key items:												
Environmental reserve adjustments	\$	-	\$	-	\$	-	\$	-	\$	(7)	\$	(7)
Restructuring, separation and other costs		-		-		-		-		(1)		(1)
All other operating income (loss)		43		28		26		27		(23)		101
Operating income (loss)		43		28		26		27		(31)		93
NET INTEREST AND OTHER EXPENSE												
Keyitems										28		28
All other net interest and other expense										15		15
										43		43
OTHER NET PERIODIC BENEFIT INCOME												
All other net periodic benefit income										1		1
NET INCOME (EXPENSE) ON ACQUISITIONS AND DIVESTITURES												
Keyitems										7		7
INCOME TAX EXPENSE (BENEFIT)												
Tax effect of key items ⁽¹⁾										(6)		(6)
Tax specific key items ⁽²⁾										6		6
All other income tax expense										20		20
										20		20
INCOME (LOSS) FROM CONTINUING OPERATIONS	\$	43	\$	28	\$	26	\$	27	\$	(86)	\$	38

⁽¹⁾ Represents the tax effect of the key items that are previously identified above.

⁽²⁾ Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. See Slide 41 for additional information.

Ashland Global Holdings Inc. and Consolidated Subsidiaries Segment Components of Key Items for Applicable Income Statement Captions for 3 Months Ended March 31, 2021

(\$ millions) Operating income (loss)		Three Months Ended March 31, 2021										
		iences Pe	ersonal Care	Specialty Additives	Intermediates	Unallocated & Other	Total					
Operating key items:												
Restructuring, separation and other costs	\$	- \$	-	\$ -	\$ -	\$ (1)	\$ (1)					
Environmental reserve adjustments		-	-	-	-	(8)	(8)					
All other operating income (loss)		35	19	19	3	(19)	57					
Operating income (loss)		35	19	19	3	(28)	48					
NET INTEREST AND OTHER EXPENSE												
Key items						7	7					
¹⁾ RepreseAls the tot blact of the the they at the second are previously identifi	ed above					16	16					
		or other matter		the definition of								
²⁾ Represents key items resulting from tax specific financial transaction	is, tax law changes (s that fall within		iax specific key fier	ns. See lable 4 Ffor	additional ²³					
** Represents key items resulting from tax specific financial transaction NET INCOME (EXPENSE) ON ACQUISITIONS AND DIVESTITURES	is, iax law changes (s that fall within	The demnion of	iax specific key fier	ns. See lable 444or	additional 23					
	is, rax iaw changes (or offici manei.	s that fall within		iax specific key fier	ns. See lable 4 F f or (5)	additional ²³ (5)					
NET INCOME (EXPENSE) ON ACQUISITIONS AND DIVESTITURES	is, tax taw changes (or officer marter.	s that tall within	The deminion of	iax specific key fier		additional					
NET INCOME (EXPENSE) ON ACQUISITIONS AND DIVESTITURES Key items	is, rax law changes (or orner maner.	s that tall within	The deminion of	iax specific key fier		additional					
NET INCOME (EXPENSE) ON ACQUISITIONS AND DIVESTITURES Key items INCOME TAX EXPENSE (BENEFIT)	is, rax law changes (or orner maner.	s that tall within	The deminion of	iax specific key fier	(5)	(5)					
NET INCOME (EXPENSE) ON ACQUISITIONS AND DIVESTITURES Key items INCOME TAX EXPENSE (BENEFIT) Tax effect of key items ⁽¹⁾	is, rax law changes (or orner maner.	s that tall within	The deminion of	iax specific key fier	(5)	(5)					
NET INCOME (EXPENSE) ON ACQUISITIONS AND DIVESTITURES Key items INCOME TAX EXPENSE (BENEFIT) Tax effect of key items ⁽¹⁾ Tax specific key items ⁽²⁾	is, rax law changes (s that tall within	The deminion of	iax specific key fier	(5) (4) (7)	(5)					

⁽¹⁾ Represents the tax effect of the key items that are previously identified above.

(2) Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. See Slide 41 for additional information.



Ashland Global Holdings Inc. and Consolidated Subsidiaries Reconciliation of Non-GAAP Data – Free Cash Flow and Adjusted Operating Income for the 3 and 6 Months Ended March 31, 2022 and 2021

(\$ millions)	Т	hree mo Mar	nths er ch 31	nded		Six months ended March 31				
Free cash flows		2022	2021		2022			2021		
Total cash flows provided by operating activities from										
continuing operations	\$	16	\$	38		31	\$	120		
Adjustments:										
Additions to property, plant and equipment		(22)		(23)		(37)		(53)		
Free cash flows	\$	(6)	\$	15		(6)		67		
Cash (inflows) outflows from U.S. Accounts Receivable Sales Program (1)		(15)		-		(5)		-		
Restructuring-related payments ⁽²⁾		1		15		5		29		
Environmental and related litigation payments ⁽³⁾		15		12		28		21		
Ongoing free cash flow	\$	(5)	\$	42	\$	22	\$	117		
Adjusted EBITDA (4)	\$	163	\$	116	\$	269	\$	218		
Ongoing free cash flow conversion (5)		-3%		36%		8%		54%		

⁽¹⁾ Represents activity associated with the U.S. Accounts Receivable Sales Program impacting each period presented.

⁽²⁾ Restructuring payments incurred during each period presented.

⁽³⁾ Represents cash outflows associated with environmental and related litigation payments which will be reimbursed by the Environmental trust.

⁽⁴⁾ See Adjusted EBITDA reconciliation.

⁽⁵⁾ Ongoing free cash flow divided by Adjusted EBITDA

	Three months ended March 31					Six months ended March 31			
Adjusted operating income	2	2022	2	021	2	022		2021	
Operating income (loss) (as reported)	\$	93	\$	48	\$	135	\$	66	
Key items, before tax:									
Restructuring, separation and other costs		1		1		2		13	
Environmental reserve adjustments		7		8		10		12	•
Capital project impairment		-		-		-			₽
Adjusted operating income (non-GAAP)	\$	101	\$	57	\$	147	\$	100	Ashland
37								0	always solving

Ashland Global Holdings Inc. Reconciliation of Non-GAAP Data – Adjusted EBITDA for 3 Months Ended March 31, 2022 and 2021

(\$ millions)

Adjusted EBITDA - Ashland Global Holdings Inc.		Three mon Marc				
		2022		2021		
Net income	\$	786	\$	41		
Income tax expense (benefit)		20		(5)		
Net interest and other expense (income)		43		23		
Depreciation and amortization		61		59		
Cash (inflows) outflows from U.S. Accounts Receivable Sales Program		910		118		
Restructuring-related payments		(748)		(16)		
Environmental and related litigation payments		(7)		5		
Operating key items (see Slides 35 and 36)		8		9		
Adjusted EBITDA	\$	163	\$	116		



Life Sciences and Personal Care Reconciliation of Non-GAAP Data – Adjusted EBITDA for 3 Months Ended March 31, 2022 and 2021

(\$ millions)	Three months March 31						
	2	2022		2021			
Adjusted EBITDA - Life Sciences							
Operating income	\$	43	\$	35			
Add:							
Depreciation and amortization		15		15			
Operating key items (see Slides 35 and 36)		-		-			
Adjusted EBITDA	\$	58	\$	50			
Adjusted EBITDA - Personal Care							
Operating income	\$	28	\$	19			
Add:							
Depreciation and amortization		21		19			
Operating key items (see Slides 35 and 36)		_		_			
Adjusted EBITDA	\$	49	\$	38			



Specialties Additives and Intermediates Reconciliation of Non-GAAP Data – Adjusted EBITDA for 3 Months Ended March 31, 2022 and 2021

(\$ millions)		Three months March 31			
		022	20	21	
Adjusted EBITDA - Specialty Additives					
Operating income	\$	26	\$	19	
Add:					
Depreciation and amortization		22		21	
Operating key items (see Slides 35 and 36)		-		_	
Adjusted EBITDA	\$	48	\$	40	
Adjusted EBITDA - Intermediates					
Operating income (loss)	\$	27	\$	3	
Add:					
Depreciation and amortization		3		4	
Operating key items (see Slides 35 and 36)		-		-	
Adjusted EBITDA	\$	30	\$	7	



Ashland Global Holdings Inc. and Consolidated Subsidiaries Reconciliation of Non-GAAP Data – Adjusted Income from **Continuing Operations** for the 3 and 6 Months Ended March 31, 2022 and 2021 The second and a second and

	Three me			nded	Six months ended				
(\$ millions)		Mar		March 31					
		2022		2021		2022		2021	
Income from continuing operations (as reported)	\$	38	\$	25	\$	70	\$	68	
Key items, before tax:									
Restructuring, separation and other costs		1		1		2		13	
Unrealized (gain) loss on securities		28		7		24		(11)	
Environmental reserve adjustments		7		8		10		12	
Net (gain) loss on acquisitions and divestitures		(7)		5		(7)		(9)	
Impairments		-		-		-		9	
Key items, before tax		29		21		29		14	
Tax effect of key items ⁽¹⁾		(6)		(4)		(6)		(2)	
Key items, after tax		23		17		23		12	
Tax specific key items:									
Restructuring and separation activity		10		-		10		(13)	
Valuation allowance		(4)		-		(4)		-	
Uncertain tax positions		-		(7)		-		(7)	
Tax specific key items ⁽²⁾		6		(7)		6		(20)	
Total key items		29		10		29		(8)	
Adjusted income from continuing operations (non-GAAP)	\$	67	\$	35	\$	99	\$	60	
Amortization expense adjustment (net of tax) $^{(3)}$		19		17		38		34	
Adjusted income from continuing operations (non-GAAP) excluding intangibles amortization expense	\$	86	\$	52	\$	137	\$	94	

(1) Represents the tax effect of the key items that are previously identified above.

(2) Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

- Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.

Uncertain tax positions: Includes the impact from settlement of certain tax positions with various tax authorities.

Amortization expense adjustment (net of tax) tax rates were 20% for the three and six months ended March 31, 2022 and 21% for the three and six months (3) ended March 31, 2021.



Charles and the state of a state

Ashland Global Holdings Inc. and Consolidated Subsidiaries Reconciliation of Non-GAAP Data – Adjusted Diluted EPS from Continuing Operations for the 3 and 6 Months Ended March 31, 2022 and 2021

Three months ended Six months ended (\$ millions) March 31 March 31 2022 2021 2022 2021 Diluted EPS from continuing operations (as reported) \$ \$ 0.40 1.20 \$ 1.10 0.66 \$ Key items, before tax: Restructuring, separation and other costs 0.02 0.02 0.04 0.21 Unrealized (gain) loss on securities 0.49 0.11 0.42 (0.18)Environmental reserve adjustments 0.14 0.12 0.19 0.19 Net (gain) loss on acquisitions and divestitures (0.12)0.08 (0.12)(0.16)Impairments 0.16 -Key items, before tax 0.53 0.33 0.53 0.22 Tax effect of key items (1) (0.12)(0.12)(0.02)Key items, after tax 0.41 0.26 0.41 0.20 Tax specific key items: Restructuring and separation activity 0.17 0.17 (0.22)Valuation allowance (0.07)-Uncertain tax positions (0.10)(0.10)-Tax specific key items ⁽²⁾ 0.10 (0.10)0.10 (0.32)Total key items 0.51 0.51 (0.12)0.16 Adjusted diluted EPS from continuing operations (non-GAAP) 1.17 0.56 \$ 1.71 0.98 Amortization expense adjustment (net of tax) $^{(3)}$ 0.33 0.28 0.66 0.55 Adjusted diluted EPS from continuing operations (non-GAAP) excluding intangibles amortization expense 1.50 0.84 \$ 2.37 1.53 \$

⁽¹⁾ Represents the tax effect of the key items that are previously identified above.

⁽²⁾ Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

- Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.

- Uncertain tax positions: Includes the impact from settlement of certain tax positions with various tax authorities.

(3) Amortization expense adjustment (net of tax) tax rates were 20% for the three and six months ended March 31, 2022 and 21% for the three and six months ended March 31, 2021.



42

